Curevac N.V. (CVAC) has released an update.
CureVac N.V., in partnership with GSK, reports encouraging interim results from their Phase 2 study on a seasonal influenza vaccine candidate, revealing significant antibody response across all flu strains and age groups. The candidate vaccine, which includes antigens for all four WHO-recommended flu strains, also demonstrated a strong safety profile, with plans to further optimize responses against influenza B strains in upcoming studies.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
